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UPDATE
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Prevalence of HIV, Hepatitis B and C, and Co-infections
Among Male Injection Drug Users in Delhi, India

India has a large injection drug user (IDU) population estimated at about 177,000 nationally with an
HIV prevalence of 7.2 percent1,2. Historically, the
presence of IDU populations and associated HIV infection was concentrated in the northeastern states
of the country. Recent evidence documents IDU populations in other parts of the country. Delhi has an
estimated 17,000 IDUs and the second highest HIV
prevalence in India at 18.3 percent3. The probability
of becoming infected with HIV after using an infected syringe ranges from 0.34 percent to 1.4 percent.
By comparison, the risk for hepatitis C (HCV) ranges
from 1.5 percent to 5 percent4. Several studies have
documented high prevalence of HIV-HCV co-infection
among IDUs in the high HIV prevalence states of
India5–6 but there is little evidence from the low HIV
prevalence states in the country.
The Population Council, in collaboration with the Sahara Center for Residential Care and Rehabilitation
(SAHARA) and the Arise—Enhancing HIV Prevention
Programs for At-Risk Populations, is implementing a
project to avert HIV infections among IDUs and their
sexual partners in Delhi. As part of the evaluation
of this project, we conducted an assessment of the

prevalence of HIV, hepatitis B (HBV) and HCV infection in a cohort of male IDUs in Delhi.

Methods
Participants were recruited from May to October
2011 through targeted outreach, peer-referral
and as walk-in clients. Recruitment criteria included having injected drugs at least once in the last
three months, aged 18 years or older, residing in or
around Delhi, willing to participate in the study, and
provide written consent. The IDUs were registered at
the five drop-in centers (DICs) operated by SAHARA
in central, east, northeast and northwest districts
of Delhi. All participants were offered baseline HIV,
HBV, and HCV testing prior to the initiation of the HIV
prevention intervention. Trained research interviewers administered close-ended questionnaire in
Hindi to collect data on socio-demographic characteristics, injecting practices, sexual behaviours,
knowledge of HIV, and utilization of harm reduction
services.

This material was produced under Arise—Enhancing HIV Prevention for At-Risk Populations. Arise implements innovative HIV prevention initiatives for
vulnerable communities, with a focus on determining cost-effectiveness through rigorous evaluations.

Laboratory testing
HIV sero-status at baseline was determined using
rapid tests as per National AIDS Control Organization (NACO) guidelines. HIV-negative status was
based on a single highly sensitive rapid test and a
positive result on two additional confirmatory rapid
tests. At the follow-up visit, all HIV-negative IDUs
were retested using a fourth generation Antigen-Antibody test followed by a confirmatory Western Blot
Assay.
For the detection of HBV infection, a serum specimen was tested for HBV surface antigen. HCV
antibodies were detected using CMIA/Electrochemiluminescence test. Active infection of HCV was
confirmed using an RNA PCR test.

Study Population
A total of 3,792 IDUs were recruited into the study.
Of those, 2,292 male IDUs who had completed
both the baseline and follow-up assessments, and
for whom confirmatory results were available, were
included in the analysis to calculate the prevalence
rates of HIV, HBV, and HCV infection. Median age
was 29 years, 48 percent were illiterate, 53 percent
were never married, and 62 percent belonged to
the Hindu religion. They came mostly from three
adjacent states of Delhi (44 percent). Although, the
majority were home-based (44 percent) many were
also living on the streets (39 percent).

sharing food; and (vi) healthy-looking people can be
infected with HIV. Further, only 8.6 percent (n=198)
had heard of HBV and 2.9 percent (n=66) had heard
of HCV.

High-risk injection behaviors
were commonly reported
Over half (52 percent) of male IDUs reported at least
one risky injection practice in the last month prior to
the survey. Sharing injection-related equipment (32
percent) and drawing from a common container (48
percent) were most frequent. Injecting with a used
needle was less frequently reported (26 percent).
Around 45 percent reported use of needle/syringe
exchange services in the previous month.

High prevalence of HIV, HCV, and
co-infection
Among those who completed the follow-up assessment, HIV prevalence was 26.0 percent (n=595)
and HCV prevalence was 53.7 percent (n=1,230).
About a fifth (19.6 percent; n=449) of IDUs had both
HIV and HCV (Figure 1). HCV prevalence reported
here denotes active HCV infection.
Figure 1 HIV and active HCV prevalence among
male IDUs, Delhi (n=2,292)
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Key Findings
Low HIV, HBV, and HVC knowledge
among male IDUs
Almost two-thirds (63 percent) of male IDUs did not
have comprehensive knowledge on HIV transmission
despite the fact that 54 percent had been injecting
for two to five years. HIV knowledge was assessed
using a six-item index comprising correct knowledge
of the participant that HIV transmission can be prevented by (i) correct and consistent use of condoms
for sex; (ii) having a monogamous uninfected sexual
partner; (iii) that sharing needles/syringes increases the risk of HIV transmission; that HIV infection
cannot spread (iv) from mosquito bites or (v) from
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HCV was common among the HIV-positive IDUs;
75.5 percent of HIV-positive IDUs tested positive for
HCV. Among HCV-infected IDUs, 36.5 percent were
HIV positive.
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Low prevalence of HBV and
co-infection of HIV
Overall, 9.7 percent (n=223) of male IDUs were infected with HBV and 4 percent (n=91) of male IDUs
had both HBV and HCV. More than a tenth (12.8
percent; n=77) of HIV positive IDUs had a HBV/HIV
co-infection, and 6.6 percent (n=39) of HIV positive
IDUs were also positive for HBV and HCV. Figure 2
illustrates the prevalence of HBV infection among
IDUs with or without HIV and HCV infections.

IDUs who were HIV positive and/or
co-infected with HCV were more likely to
engage in risky injection behavior than
IDUs who were HIV and HCV negative
HIV/HCV negative IDUs were less likely to have
practiced risky injection in the last month compared
to those infected with either or both infections. A
little more than a third (36.4 percent) had previously
shared needle/syringes, back/front loaded or split
drugs, drawn up drugs from common containers, or
received pre-filled injection, or shared equipment in
the last month. However, these risky injection practices were more frequently reported by HCV positive
male IDUs (62.4 percent) and HIV/HCV co-infected
IDUs (65.3 percent).

Program Implications and
Recommendations
Despite the availability of targeted intervention programs that recommend HIV testing and counseling
every six months, the majority of male IDUs did not
have comprehensive HIV knowledge. Awareness of
HBV and HCV was even lower. Counseling should
include information about HBV and HCV prevention. Counselors should assess comprehensive HIV
knowledge among persons undergoing HIV testing
at the end of every counseling session.
Hepatitis C prevalence and co-infection with HIV was
extremely high in this cohort of male IDUs and high
risk injection practices were more frequent among
infected IDUs. This has serious implications for
onward transmission to injecting and sex partners of
these IDUs. Further, HCV infection has a strong link
with liver chronicity and hepatocellular carcinoma.
Thus HCV prevention must be a priority in targeted
interventions for IDUs. Given the prohibitively high
cost of HCV treatment and the lack of vaccine for
HCV, primary prevention such as safer injection
practices and prevention of drug injection initiation
must be emphasized. Although targeted intervention
programs provide sterile needles and syringes and
many IDUs use this services, this does not necessarily translate into safe behaviors in a sustained
fashion. HIV prevention programs need to review
strategies to engineer a long-term behavior change.

Figure 2 Prevalence of HBV and co-infection with HIV and HCV (n=2,292)
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